NEW YORK--(BUSINESS WIRE)--
Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is reported beginning deployment of its FDA-cleared INSPIRA ART100 system at a leading New York cardiothoracic program ranked among the top 15% nationally, marking a significant commercialization milestone in a sector experiencing unprecedented M&A activity. The medtech industry saw multiple billion-dollar acquisitions in 2024, including Johnson & Johnson's $13.1 billion acquisition of Shockwave Medical, Edwards' $4.2 billion sale of its Critical Care business to BD, and Boston Scientific's $3.7 billion Axonics purchase.
The mechanical ventilation market represents a $19 billion global opportunity ripe for innovation. Traditional ventilators show mortality rates exceeding 50% for patients with severe respiratory failure, requiring medically-induced comas and invasive intubation that lead to complications including lung damage and infections.
Inspira's approach aims to provide respiratory support without intubation. The company's technology will be showcased this week at the American Society of Extracorporeal Technology Conference in San Diego, exposing it to leading perfusion professionals nationwide.
The company's AI-powered HYLA blood sensor recently achieved 96% accuracy in a key blood parameter in clinical trials at Sheba Hospital (ranked among the world's top 8 hospitals by Newsweek). The technology demonstrated 92.3% accuracy in detecting oxygen deficiencies while providing real-time monitoring without blood draws.
Inspira's integrated technology platform centers on the VORTX Oxygen Delivery System, a novel approach to blood oxygenation protected by 32 patent claims. This is complemented by the HYLA Blood Sensor, targeting the $5.7 billion blood gas analyzer market. The company's flagship INSPIRA ART500 system (also referred to as Gen 2) aims to provide direct blood oxygenation without mechanical ventilation, potentially allowing patients to remain awake during treatment. "Once fully integrated, our INSPIRA ART500 is intended to be equipped with the HYLA blood sensor," noted CEO Dagi Ben-Noon in a recent shareholder letter. Unlike the FDA-cleared ART100 system designed for cardiopulmonary bypass, the ART500 targets to directly address respiratory failure as a full ecosystem offering a new vision for respiratory care.
Inspira has established manufacturing collaboration with Zriha Medical and distribution agreements with Glo-Med Networks, with systems now being deployed to U.S. hospitals.
With approximately 20 million patients requiring respiratory support annually and medtech M&A activity accelerating (275 deals worth $34 billion in Q3 2024, a 35% increase year-over-year), Inspira represents a company with FDA-cleared technology already deployed in clinical settings while advancing additional products through the regulatory pipeline. The surge in medtech acquisitions highlights the premium strategic buyers are willing to pay for innovative medical technologies addressing significant clinical needs, with eight transactions exceeding $1 billion in 2024 alone.
News Highlights from Inspira:
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains and is a form of paid promotional content for Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: .
View source version on businesswire.com:
